期刊文献+

瑞舒伐他汀中间体的合成工艺改进 被引量:6

Improvement in Synthesis Method of the Intermediate of Rosuvastatin
下载PDF
导出
摘要 采用B iginelli嘧啶酮缩合反应,以4-氟苯甲醛、异丁酰乙酸甲脂和硫脲为原料,在质子酸存在下经缩合、甲基化、氧化、亲核取代、还原和氧化反应,合成了降血脂药物瑞舒伐他汀(Rosuvastatin)的中间体嘧啶醛化合物(Ⅶ),总收率为32.5%,与H irai K所申请的专利(US 5 260 440,1993)的方法相比,不仅缩短了反应步骤,而且收率提高了14.5%。化合物的结构经1HNMR,IR和MS进行了确证。 Applying the Biginelli reaction, reacting 4-fluorobenzaldehyde with methyl isobutyrylacetate and thiourea in the presence of a protonic compound, then through methylation, oxidation, necleophilic substitution, reduction and oxidation, the pyrimidine aldehyde intermediate of Rosuvatatin ( for reduction of cholesterol levels in patients with hypercholesterolaemia)was synthesized in 32.5% yield. Compared with the literatures, not only the synthesis step was shorten,but also the yield was improved by 14.5 %. Structures of the compounds were confirmed by ^1HNMR,IR and MS.
出处 《精细化工》 EI CAS CSCD 北大核心 2006年第2期192-194,共3页 Fine Chemicals
关键词 Biginelli缩合 瑞舒伐他汀 嘧啶醛 Biginelli condensation Rosuvastatin pyrimidine aldehyde
  • 相关文献

参考文献10

  • 1Jeremy Quirk,Mark Thornton,Peter Kirkpatrick.Rosuvastatincalcium[J],News&Analysis,2003,2,769-770.
  • 2田东华,王永红.新的他汀类降脂药——Rosuvastatin[J].河北医药,2003,25(6):460-461. 被引量:3
  • 3Hull CK,Penman AD,Smith CK,et al.Quantification of rosuvastatin in human plasma by automated solidphase extraction using tandem mass spectrome tricdetection[J].J Chromatogr B Analyt Technol Biomed Life Sci,2002,772:219.
  • 4Lafus U,Gertz K,Dimagl U,et al.Rosuvastatin,a new HMG-CoA reductase inhibitor,uprequlates endothelial nitric oxide synthase and protects from schemic stroke in mice[J].Brain Res,2002,28,942:23-30.
  • 5Watanabe M,Koike H,Ishiba T,et al.Synthesis and biological activity of methane sulfonamide pyrimidine-and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates,a novel series of HMG-CoA reductase inhibitors[J].Bioorg Med Chem,1997,5:437-444.
  • 6Hirai K,Ishiba T,Koike H,et al.Pyrimidine derivs.as HMG-CoA reductase inhibitors[P].US:5 260 440,1993-12-09.
  • 7Kumar,Yutendra.Process for the preparation of Rosuvastatin[P].WO:03 097 614,2003-01-23.
  • 8Kamaljit Singh,Jasbir Singh,Prasant K Deb,et al.An expedient protocol of the Biginelli dihydropyrimidine synthesis using carbonyl equivalents[J].Tetrahedron,1999,55:12873-12880.
  • 9C OLIVEER Kappe.Recent advances in the Biginelli dihydropyrimidine synthesis:new tiricks from an old dog[J].Acc Chem Res 2000,33:879-888.
  • 10M Shamim akhtar,M Seth,A PBHADU RI.Synthesis of 2,3-dihydro-5H-thiazolo[3,2-a]pyrimidines & tetrasubstituted dihydropyrimidine derivatives as anthelmintic agents[J].Indian J.Chem,1997,26B:556-567.

二级参考文献11

  • 1Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemia patients: a randomized, double-blind study. J Cardiovasc Risk,2001,8:383-390.
  • 2Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin in patients with type Ⅱa or Ⅱb hypercholesterolemia. Am J Cardiol, 2002,89:268-275.
  • 3Schuster H. High risk/high priority:familial hyper cholesterole a paradigm for molecular medicine. Atheroscler Suppl, 2002,2: 27-32.
  • 4Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann Pharmacother,2002,36:93-101.
  • 5Laufs U,Gertz K, Dimagl U,et al. Rosuvastatin,a new MHG-CoA reductase inhibitor, uprequlates endothelial nitric oxide synthase and protects from schemic stroke in mice. Brain Rea,2002,28,942:23-30.
  • 6La Rosa JC,He J, Vupputuri HS.Effect of statin on risk of coronary disease:Ameta-analysis of randomized controlled trials. JAMA, 1999,282:2340-2346.
  • 7Auerbach BJ,Dash D, Bousley D, et al.The ACAT inhibitor, avasimibe, reduces aortic cholesterol content in apoE knockout mice, independent of its plasma hypocholesterolemic effects. Atherosclerosis, 2000, (5) :65.
  • 8Bruckert. New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology,2002,97:59-66.
  • 9Hull CK, Penman AD, Smith CK, et al. Quantification of rosuvastatin in human plasma by automated solidphase extraction using tandem mass spectrometric detection.J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 772: 219-228.
  • 10Davidison MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidemia. Expert Opin Investig Durgs, 2002,11 : 125-141.

共引文献2

同被引文献45

  • 1刘国庆,蒋成君,陈光顺.瑞舒伐他汀合成路线图解[J].中国医药工业杂志,2005,36(9):585-587. 被引量:4
  • 2魏嘉陵,林畅伟.用加校正因子的主成分自身对照法测定苯扎贝特中杂质氯苯酪胺的含量[J].药物分析杂志,2006,26(12):1848-1850. 被引量:17
  • 3JonesPH,DavidsonMH,SteinEA.Comparisonoftheefficacyandsafetyofrosuvastatinversusatorvastatin,simvastatin,andpravastatinacrossdoses(STELLARTrial)[J].Am.J.Cardiol,2003,93:152-160.
  • 4SchusterH,BarterPJ,StenderS.Effectsofswitchingstainsonachievementoflipidgoals:measuringeffectivereductions in cholesterol using rosuvastatin therapy(MERCURY1)study[J].Am.Heart.J.,2004,147:705-712.
  • 5SchwartzG,BologneseMA,TremblayBP.Efficacyandsafetyofrosuvastatinandatorvastatininpatientswithhypercholesterolemiaandahighriskofcoronaryheartdisease:arandomized,controlledtrail[J].Am.Heart.J.,2004,148:e4.
  • 6KürtiL,CzakóB.Strategicapplicationsofnamedreactionsinorganicsynthesis[M].Netherlands:ElsevierAcademicPress,2005.
  • 7HaruoK,MikioK,PhilipTN,etal.EP[P],1155015,2001.
  • 8KentaroH,TeruyukiI,HaruoK,etal.EP[P],0521471,1993.
  • 9HuangZB(黄仲斌),DaiLH(戴连华),ChenZ(谌谆),etal.CN[P].101376647(中国专利),2009.
  • 10LiuRH,LiangX M,DongC Y,etal.Transitionmetalfree:ahighlyefficientcatalyticaerobicalcoholoxidationprocess[J].J.Am.Chem.Soc.,2004,126:4112-4113.

引证文献6

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部